Canine Inflammatory Bowel Disease: Management and Welfare

Inflammatory Bowel Disease in Dogs

Inflammatory bowel disease (IBD) in dogs encompasses a group of chronic, idiopathic gastrointestinal disorders characterised by persistent or recurrent gastrointestinal signs and histological evidence of intestinal inflammation. Managing IBD requires long-term commitment from owners and veterinarians, with welfare-oriented treatment aiming to achieve remission and maintain quality of life.

Types and Pathophysiology

Canine IBD is classified by the predominant inflammatory cell type on intestinal biopsy:

• Lymphoplasmacytic enteritis/colitis: Most common; responsive to dietary and immunosuppressive therapy
• Eosinophilic gastroenteritis: Often associated with food allergy; may respond to dietary management
• Granulomatous colitis: Adherent-invasive E. coli (AIEC) associated; Boxer and French Bulldog predisposition; requires enrofloxacin treatment

The underlying mechanism involves abnormal immune activation against dietary antigens or commensal bacteria in genetically susceptible individuals. Dysbiosis (altered gut microbiome) plays an important role.

Welfare Impacts

IBD causes chronic, often intermittent discomfort and distress including: chronic diarrhoea (sometimes bloody), vomiting, weight loss, lethargy, and abdominal pain. Dogs with uncontrolled IBD have significantly reduced quality of life. Protein-losing enteropathy (PLE) — severe protein loss from the inflamed gut — causes hypoalbuminaemia, oedema, ascites, and a poor prognosis.

Diagnostic Approach

Diagnosis of IBD requires exclusion of other causes of chronic gastrointestinal signs — particularly dietary-responsive disease and chronic enteropathy. Full diagnostic workup includes: serum B12 and folate, faecal parasitology, dietary trial (novel protein or hydrolysed diet for 6-8 weeks), and intestinal biopsy via endoscopy or laparotomy for histopathological classification.

Treatment

Dietary management: Novel protein diets (duck, venison, rabbit, insect protein) or hydrolysed diets remove potential dietary antigens. Many dogs with dietary-responsive chronic enteropathy achieve long-term remission with dietary management alone — a welfare-positive outcome avoiding long-term immunosuppression.

Immunosuppressive therapy: Prednisolone is first-line for true IBD; cyclosporin, azathioprine, or chlorambucil are added for steroid-refractory disease or to allow steroid dose reduction. Treatment is titrated to the minimum dose maintaining remission.

Gut microbiome support: Prebiotics, probiotics, and faecal microbiota transplantation (FMT) are increasingly used as adjuncts to conventional IBD treatment.

Prognosis and Long-term Welfare

Many dogs with IBD achieve long-term remission with appropriate management, maintaining good quality of life. PLE cases have a more guarded prognosis. Regular monitoring of clinical signs, body weight, and (for severe cases) serum albumin enables early detection of relapse and treatment adjustment.

This page is part of the Animal Welfare Hub — providing evidence-based information to improve the lives of animals. Return to home.